Hierarchical and redundant roles of activating FcγRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies

Journal of Virology

Volumn 91, Issue 7, 2017, Pages

  Van den Hoecke, Silvie ^a,b   Ehrhardt, Katrin ^c   Kolpe, Annasaheb ^a,b   El Bakkouri, Karim ^a,b,f   Deng, Lei ^a,b,g   Grootaert, Hendrik ^a,b   Schoonooghe, Steve ^a,d   Smet, Anouk ^a,b   Bentahir, Mostafa ^a,b,h   Roose, Kenny ^a,b   Schotsaert, Michael ^a,b,i   Schepens, Bert ^a,b   Callewaert, Nico ^a,b   Nimmerjahn, Falk ^e   Staeheli, Peter ^c   Hengel, Hartmut ^c   Saelens, Xavier ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF FREIBURG   (Germany)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f KING FAHAD MEDICAL CITY   (Saudi Arabia)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Fc receptors; IgG antibody isotype; Influenza A virus; M2e; Mechanism of protection; Viral infection

Indexed keywords

CD16 ANTIGEN; FC RECEPTOR; FC RECEPTOR I; FC RECEPTOR IV; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INFLUENZA VIRUS HEMAGGLUTININ; MATRIX PROTEIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 37; MONOCLONAL ANTIBODY 65; UNCLASSIFIED DRUG; VIRAL PROTEIN; ANTIVIRUS AGENT; IMMUNOGLOBULIN G; INFLUENZA VACCINE; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA A; MDCK CELL LINE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; SURVIVAL RATE; VIRUS LOAD; ADAPTIVE IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CARBOHYDRATE ANALYSIS; CONFORMATION; GLYCOSYLATION; HEK293 CELL LINE; HYBRIDOMA; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); KNOCKOUT MOUSE; PHYSIOLOGY; PROTEIN PROCESSING; VIROLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIVIRAL AGENTS; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; GLYCOSYLATION; HEK293 CELLS; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, IGG; VIRAL MATRIX PROTEINS;

EID: 85015149634     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02500-16     Document Type: Article

References (38)

1. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157-1163. https://doi.org/10.1038/13484.
2. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186:1022-1031. https://doi.org/10.4049/jimmunol.0902147.
3. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. 1990. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64:1375-1377.
4. Lamb RA, Zebedee SL, Richardson CD. 1985. Influenza virus-M2 protein is an integral membrane-protein expressed on the infected-cell surface. Cell 40:627-633. https://doi.org/10.1016/0092-8674(85)90211-9.
5. Zebedee SL, Lamb RA. 1988. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62:2762-2772.
6. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W, Couch RB, Gerhard W. 2006. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3:102. https://doi.org/10.1186/1743-422X-3-102.
7. Zhong W, Reed C, Blair PJ, Katz JM, Hancock K. 2014. Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans. J Infect Dis 209:986-994. https://doi.org/10.1093/infdis/jit811.
8. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X. 2008. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 283:11382-11387. https://doi.org/10.1074/jbc.M800650200.
9. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW. 2004. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22:2993-3003. https://doi.org/10.1016/j.vaccine.2004.02.021.
10. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. 2004. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172: 5598-5605. https://doi.org/10.4049/jimmunol.172.9.5598.
11. Schotsaert M, De Filette M, Fiers W, Saelens X. 2009. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8:499-508. https://doi.org/10.1586/erv.09.6.
12. Wang BZ, Gill HS, Kang SM, Wang L, Wang YC, Vassilieva EV, Compans RW. 2012. Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand. Clin Vaccine Immunol 19:1119-1125. https://doi.org/10.1128/CVI.00153-12.
13. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. 2011. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29:5145-5152. https://doi.org/10.1016/j.vaccine.2011.05.041.
14. Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, Koriazova L, Madura L, Shapiro L, Matsumoto A, Mikayama T, Kubo RT, Sarawar S, Cheroutre H, Kato S. 2008. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80:168-177. https://doi.org/10.1016/j.antiviral.2008.06.002.
15. Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, Pumpens P, Saudan P, Bachmann MF. 2012. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 42:863-869. https://doi.org/10.1002/eji.201041225.
16. DiLillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 20:143-151. https://doi.org/10.1038/nm.3443.
17. Cho KJ, Schepens B, Seok JH, Kim S, Roose K, Lee JH, Gallardo R, Van Hamme E, Schymkowitz J, Rousseau F, Fiers W, Saelens X, Kim KH. 2015. Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody. J Virol 89: 3700-3711. https://doi.org/10.1128/JVI.02576-14.
18. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. 2003. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325:979-989. https://doi.org/10.1016/S0022-2836(02)01250-0.
19. Jefferis R, Lund J, Pound JD. 1998. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 163:59-76. https://doi.org/10.1111/j.1600-065X.1998.tb01188.x.
20. Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H. 2010. Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol 185:6876-6882. https://doi.org/10.4049/jimmunol.1002600.
21. Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M. 2014. Glycoengineering of therapeutic antibodies enhances monocyte/macrophagemediated phagocytosis and cytotoxicity. J Immunol 192:2252-2260. https://doi.org/10.4049/jimmunol.1301249.
22. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733-26740. https://doi.org/10.1074/jbc.M202069200.
23. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466-3473. https://doi.org/10.1074/jbc .M210665200.
24. Corrales-Aguilar E, Trilling M, Hunold K, Fiedler M, Le VT, Reinhard H, Ehrhardt K, Merce-Maldonado E, Aliyev E, Zimmermann A, Johnson DC, Hengel H. 2014. Human cytomegalovirus Fcgamma binding proteins gp34 and gp68 antagonize Fcgamma receptors I, II and III. PLoS Pathog 10:e1004131. https://doi.org/10.1371/journal.ppat.1004131.
25. Corrales-Aguilar E, Trilling M, Reinhard H, Merce-Maldonado E, Widera M, Schaal H, Zimmermann A, Mandelboim O, Hengel H. 2013. A novel assay for detecting virus-specific antibodies triggering activation of Fcgamma receptors. J Immunol Methods 387:21-35. https://doi.org/10.1016/j.jim.2012.09.006.
26. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. 2005. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23:41-51. https://doi.org/10.1016/j.immuni.2005.05.010.
27. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. 2014. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol 14:94-108. https://doi.org/10.1038/nri3582.
28. Bruhns P. 2012. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119:5640-5649. https://doi.org/10.1182/blood-2012-01-380121.
29. Nimmerjahn F, Ravetch JV. 2011. FcgammaRs in health and disease. Curr Top Microbiol Immunol 350:105-125. https://doi.org/10.1007/82_2010_86.
30. Ibanez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, Roels S, Pollard C, Schepens B, Grooten J, Fiers W, Saelens X. 2013. M2edisplaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. PLoS One 8:e59081. https://doi.org/10.1371/journal.pone.0059081.
31. Song JM, Van Rooijen N, Bozja J, Compans RW, Kang SM. 2011. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A 108:757-761. https://doi.org/10.1073/pnas.1012199108.
32. Nimmerjahn F, Lux A, Albert H, Woigk M, Lehmann C, Dudziak D, Smith P, Ravetch JV. 2010. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A 107: 19396-19401. https://doi.org/10.1073/pnas.1014515107.
33. Lee SM, Gardy JL, Cheung CY, Cheung TK, Hui KP, Ip NY, Guan Y, Hancock RE, Peiris JS. 2009. Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages. PLoS One 4:e8072. https://doi.org/10.1371/journal.pone.0008072.
34. Mancardi DA, Iannascoli B, Hoos S, England P, Daeron M, Bruhns P. 2008. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 118:3738-3750. https://doi.org/10.1172/JCI36452.
35. Coffman RL, Sher A, Seder RA. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33:492-503. https://doi.org/10.1016/j.immuni.2010.10.002.
36. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. 2001. Fc receptormediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166:7381-7388. https://doi.org/10.4049/jimmunol.166.12.7381.
37. DiLillo DJ, Palese P, Wilson PC, Ravetch JV. 2016. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 126:605-610. https://doi.org/10.1172/JCI84428.
38. Laroy W, Contreras R, Callewaert N. 2006. Glycome mapping on DNA sequencing equipment. Nat Protoc 1:397-405. https://doi.org/10.1038/nprot.2006.60.